Immunomodulation by radiotherapy in tumour control and normal tissue toxicity
UM Cytlak, DP Dyer, J Honeychurch… - Nature Reviews …, 2022 - nature.com
Radiotherapy (RT) is a highly effective anticancer treatment that is delivered to more than
half of all patients with cancer. In addition to the well-documented direct cytotoxic effects, RT …
half of all patients with cancer. In addition to the well-documented direct cytotoxic effects, RT …
Radiation-induced fibrosis: mechanisms and implications for therapy
JM Straub, J New, CD Hamilton, C Lominska… - Journal of cancer …, 2015 - Springer
Purpose Radiation-induced fibrosis (RIF) is a long-term side effect of external beam
radiation therapy for the treatment of cancer. It results in a multitude of symptoms that …
radiation therapy for the treatment of cancer. It results in a multitude of symptoms that …
Immune mechanisms in pulmonary fibrosis
Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis, represents a chronic and
progressive disease with high mortality and limited therapeutic options. Excessive …
progressive disease with high mortality and limited therapeutic options. Excessive …
The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis
Recruitment of immune cells to the site of inflammation by the chemokine CCL1 is important
in the pathology of inflammatory diseases. Here, we examined the role of CCL1 in …
in the pathology of inflammatory diseases. Here, we examined the role of CCL1 in …
Inhibition of Bcl-2/xl with ABT-263 selectively kills senescent type II pneumocytes and reverses persistent pulmonary fibrosis induced by ionizing radiation in mice
J Pan, D Li, Y Xu, J Zhang, Y Wang, M Chen… - International Journal of …, 2017 - Elsevier
Purpose Ionizing radiation (IR)–induced pulmonary fibrosis (PF) is an irreversible and
severe late effect of thoracic radiation therapy. The goal of this study was to determine …
severe late effect of thoracic radiation therapy. The goal of this study was to determine …
CXCL12/CXCR4: an amazing challenge and opportunity in the fight against fibrosis
X Wu, L Qian, H Zhao, W Lei, Y Liu, X Xu, J Li… - Ageing research …, 2023 - Elsevier
Fibrosis is a pathological process caused by abnormal wound healing response, which
often leads to excessive deposition of extracellular matrix, distortion of organ architecture …
often leads to excessive deposition of extracellular matrix, distortion of organ architecture …
Pericytes, mesenchymal stem cells and their contributions to tissue repair
SP Wong, JE Rowley, AN Redpath, JD Tilman… - Pharmacology & …, 2015 - Elsevier
Regenerative medicine using mesenchymal stem cells for the purposes of tissue repair has
garnered considerable public attention due to the potential of returning tissues and organs …
garnered considerable public attention due to the potential of returning tissues and organs …
CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment
Chemokines are crucial autocrine and paracrine players in tumor development. In particular,
CXCL12, through its receptors CXCR4 and CXCR7, affects tumor progression by controlling …
CXCL12, through its receptors CXCR4 and CXCR7, affects tumor progression by controlling …
Effects of CTGF blockade on attenuation and reversal of radiation-induced pulmonary fibrosis
S Bickelhaupt, C Erbel, C Timke… - JNCI: Journal of the …, 2017 - academic.oup.com
Background: Radiotherapy is a mainstay for the treatment of lung cancer that can induce
pneumonitis or pulmonary fibrosis. The matricellular protein connective tissue growth factor …
pneumonitis or pulmonary fibrosis. The matricellular protein connective tissue growth factor …
CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent
J Wang, BA Tannous, MC Poznansky, H Chen - Pharmacological research, 2020 - Elsevier
Abstract AMD3100 (plerixafor), a CXCR4 antagonist, has opened a variety of avenues for
potential therapeutic approaches in different refractory diseases. The CXCL12/CXCR4 axis …
potential therapeutic approaches in different refractory diseases. The CXCL12/CXCR4 axis …